Clinical Trials Logo
  1. Home
  2. Neovascular Glaucoma
  3. NCT01370135

Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma — LucNVG0108  

Neovascular Glaucoma Clinical Trial

Official title:
An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma

Clinical Trial Summary

Proliferative ischemic retinopathies lead to a formation of abnormal vessels on the iris surface induced by an increased level of vascular endothelial growth factor (VEGF). In progressive stages fibrovascular membranes occlude the anterior chamber angle which inhibits aqueous outflow resulting in neovascular glaucoma. The increased intraocular pressure is often difficult to control and frequently results in loss of vision.

The aim of this study is to analyze the short- and long-term outcome after adjuvant intraocular Ranibizumab application in patients with neovascular glaucoma and rubeosis and to analyze the role of ranibizumab within a holistic treatment regime.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01370135
Study type Interventional
Source University of Luebeck
Contact
Status Completed
Phase N/A
Start date November 2008
Completion date July 2011
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00491712 - Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection N/A
Recruiting NCT04519619 - Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Completed NCT04970251 - Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma N/A
Completed NCT02805257 - Ahmed Glaucoma Valve Surgery With Mitomycin-C Phase 2
Recruiting NCT02067013 - Analysis of Aqueous and Vitreous Humor Phase 2
Completed NCT00524758 - Oculusgen (Ologen) Glaucoma MMC Control in Estonia Phase 3
Withdrawn NCT00727038 - Lucentis for New Onset Neovascular Glaucoma Phase 1/Phase 2
Not yet recruiting NCT02947867 - Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Phase 2/Phase 3
Completed NCT01711879 - Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma N/A
Active, not recruiting NCT02260219 - Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma N/A
Withdrawn NCT00441181 - Effects of Travoprost on Neovascular Glaucoma N/A
Completed NCT01051583 - Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma Phase 2
Completed NCT05156021 - A Study on the Treatment Strategy of NVG Secondary to PDR N/A
Terminated NCT01301378 - Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube N/A
Not yet recruiting NCT05316142 - Any Unique Identifier Assigned to the Protocol by the Sponsor N/A
Recruiting NCT04844619 - KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial Phase 1
Completed NCT03154892 - The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma N/A